Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. (ADVM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
advm · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Adverum Biotechnologies, Inc. (ADVM) measures how much investors pay for each dollar of the company's trailing earnings. ADVM's current PE ratio of N/A is calculated by dividing its stock price of $4.36 by its TTM earnings per share of -$8.70.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2012 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Adverum Biotechnologies, Inc.You ADVM | $96M | N/A | — | -$8.70 |
 ALX Oncology Holdings Inc. ALXO | $214M | N/A | — | -$1.90 |
 Artiva Biotherapeutics, Inc. ARTV | $176M | N/A | — | -$3.43 |
 aTyr Pharma, Inc. ATYR | $46M | N/A | — | -$0.80 |
 Biomea Fusion, Inc. BMEA | $71M | N/A | — | -$1.18 |
 Precision BioSciences, Inc. DTIL | $88M | N/A | — | -$3.63 |
 Fractyl Health, Inc. Common Stock GUTS | $51M | N/A | — | -$1.86 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-6.62 | — | |
2023-12-31 FY2023 | — | $-2.11 | — | |
2022-12-31 FY2022 | — | $-2.67 | — | |
2021-12-31 FY2021 | — | $-1.48 | — | |
2020-12-31 FY2020 | — | $-1.26 | — | |
2019-12-31 FY2019 | — | $-0.87 | — | |
2018-12-31 FY2018 | — | $-1.18 | — | |
2017-12-31 FY2017 | — | $-1.29 | — | |
2016-12-31 FY2016 | — | $-3.14 | — | |
2015-12-31 FY2015 | — | $-1.86 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Adverum Biotechnologies, Inc. (ADVM) measures how much investors pay for each dollar of the company's trailing earnings. ADVM's current PE ratio of N/A is calculated by dividing its stock price of $4.36 by its TTM earnings per share of -$8.70.
Frequently asked questions
ADVM pe ratio · 6 questionsADVM's current PE ratio is N/A as of 2026-06-09, based on a stock price of $4.36 and TTM EPS of -$8.70. Data sourced from Financial Modeling Prep via ADVM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Adverum Biotechnologies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09